80. Machiels, J.P., et al., Afatinib versus methotrexate as second -line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX -Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol, 2015. 16 (5): p. 583-94.